ReCOV

ReCOV
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular

ReCOV is a COVID-19 vaccine candidate developed by Jiangsu Rec-Biotechnology Co Ltd.[1][2][3][4]

References

  1. Clinical trial number NCT04818801 for "Safety, Reactogenicity and Immunogenicity Study of ReCOV" at ClinicalTrials.gov
  2. Clinical trial number NCT05084989 for "Efficacy, Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)" at ClinicalTrials.gov
  3. Allott A, McDonald L (24 June 2021). "New Covid-19 vaccine developed in China is being tested on Kiwis". Stuff. Retrieved 23 December 2021.
  4. "Coronavirus: China-made 'ReCov' vaccine may be better than Pfizer-BioNTech's, New Zealand doctor says; Sydney faces 'scariest period' of pandemic". South China Morning Post. 24 June 2021. Retrieved 23 December 2021.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.